Streetbeat News

Earnings

TCRX

TScan Therapeutics has presented updated Phase 1 clinical results for TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR. These results could indicate significant progress in their development pipeline, potentially impacting the company's stock performance.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 12:16 pm

CRGO

Freightos (NASDAQ:CRGO) reported Q4 2023 adjusted EPS of $(0.06), surpassing the $(0.12) estimate, and sales of $5.26M, exceeding the $5.22M estimate. This represents a significant improvement over the previous year, with a 92.94% increase in EPS and an 8.43% increase in sales.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 12:14 pm

FIS

Fidelity National Info (FIS) reported Q4 earnings of $0.94 per share, meeting analyst estimates. However, its quarterly sales of $2.51 billion fell short of the $2.53 billion estimate, marking a 32.42% decrease from the previous year's $3.71 billion.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 12:06 pm

CLDX

Celldex Therapeutics (NASDAQ:CLDX) reported Q4 earnings with a per-share loss of $(0.83), missing the $(0.74) estimate, and sales of $4.13M, surpassing the $840.00K estimate. This represents a 48.21% increase in losses and a 156.04% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 12:06 pm

FIS

FIS provided its Q1 adjusted EPS guidance in the range of $0.94-$0.97, slightly below the $0.95 estimate. Revenue guidance for Q1 is set at $2.43B-$2.455B, marginally below the $2.46B estimate. For FY24, FIS forecasts an adjusted EPS of $4.66-$4.76, surpassing the $4.42 estimate, with revenue projections of $10.1B-$10.15B, slightly below the $10.12B estimate.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 12:05 pm

BRK-B

LI

TEVA

Li Auto Inc. reported Q4 earnings surpassing estimates with adjusted earnings of 30 cents per share and sales of $5.88 billion, leading to an 8% pre-market stock surge. Other stocks like ImmunityBio, Bowlero Corp, Teva Pharmaceutical, Amer Sports, SES AI Corporation, Berkshire Hathaway, and BioCryst Pharmaceuticals also saw pre-market gains. Teva announced U.S. approval of SIMLANDI, and Berkshire Hathaway plans to maintain its investment in Occidental Petroleum.

Portfolio Pulse from Avi Kapoor

February 26, 2024 | 12:03 pm

BCRX

BioCryst Pharmaceuticals forecasts its fiscal year 2024 net revenue for Orladeyo to be between $380M-$400M. The company anticipates operating profit in 2024, with expectations of approaching positive EPS and achieving positive cash flow in the second half of 2025.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 12:03 pm

PPC

Pilgrims Pride (NASDAQ:PPC) reported Q4 adjusted earnings of $0.59 per share, surpassing the $0.40 estimate, marking a 220.41% increase from last year's losses. Sales reached $4.53B, exceeding the $4.47B estimate and showing a 9.72% increase from the previous year.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 12:02 pm

BCRX

BioCryst Pharma (BCRX) reported Q4 adjusted EPS of $(0.28), missing the $(0.24) estimate, but sales of $93.40M exceeded the $90.01M estimate. This represents a 26.32% decrease in losses and a 17.42% increase in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 12:01 pm

FIS

Fidelity National Information Services, Inc. (FIS) reported its Q4 2023 earnings with a GAAP EPS of $0.94, meeting the analyst consensus estimate.

Portfolio Pulse from Benzinga Newsdesk

February 26, 2024 | 12:01 pm